Genomic Health and Biocartis Group NV announce they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score Test on Biocartis’ Idylla platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world. Although prostate cancer is the most common cancer among men, it can fortunately often be treated successfully. The Oncotype DX GPS test is the only commercially available tissue biopsy-based, multi-gene test that has been clinically validated to assess the aggressiveness of prostate cancer in men with clinically low-risk or favorable intermediate-risk cancer at the time of diagnosis, helping to make better informed and more personalized treatment decisions. Today, this test has been validated in more than 4,500 patients, which is described in 18 publications. Herman Verrelst, Chief Executive Officer of Biocartis, commented: “I am very happy to announce the expansion of our collaboration with Genomic Health, with whom we are now entering the domain of urological cancer testing which is a promising new market for Idylla. Once available, the Idylla Oncotype DX GPS test can support pathology labs and also local urology centers across the world in making better informed treatment decisions for patients with prostate cancer.”
